Another two DNA vaccines, INO-5401 (synthetic DNA plasmids encoding human telomerase reverse transcriptase, Wilms’ tumor gene 1, and prostate-specific membrane antigen), and INO-9012 (synthetic DNA plasmid encoding IL-12), in combination with the PD-1 inhibitor cemiplimab, are being investigated in an ongoing phase I/II trial (NCT03491683) for newly diagnosed GBM patients [111]. Here, PDCD1 is linked to glioblastoma.